Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 28, 2007

Gene Logic to Reposition Lundbeck Candidates

  • Gene Logic will work with H. Lundbeck to reposition some of the latter’s drug candidates. These compounds were discontinued or de-prioritized in clinical trials for reasons other than safety, according to the companies.

    The drug repositioning agreement provides for milestones and royalties similar to those paid for development-stage in-licensing deals, discounted to account for Lundbeck's contribution as the originator of the compound. Gene Logic retains the option to exclusively license any candidate for which Gene Logic identifies a potential new use and Lundbeck chooses not to pursue. In such a case Lundbeck will be payed success-based milestones and royalties.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »